Sobre posibles medicamentos para tratar la infección por SARS-CoV-2, causante de la COVID-19: ¿hay alguna esperanza? / About possible medications to treat SARS-CoV-2 infection, which causes COVID-19: is there any hope?
DOI:
https://doi.org/10.24875/RMIMSS.M20000023Palabras clave:
Virus del SARS-CoV-2, Infecciones por Coronavirus, Terapéutica, Pandemias / SARS-CoV-2 Virus, Coronavirus Infections, Therapeutics, PandemicsResumen
Resumen
Hasta el día de hoy no se cuenta con un tratamiento para los pacientes infectados con SARS-CoV-2. Se están llevando a cabo estudios en varios países y algunos han arrojado resultados prometedores; sin embargo, aún no se ha logrado identificar un tratamiento efectivo para combatir la COVID-19, una de las amenazas más serias que ha sufrido la humanidad en los últimos 100 años.
Abstract
To date, there is no treatment for patients infected with SARS-CoV-2. Several studies are being carried out in several countries and some have yielded promising results; however, still no effective treatment has been identified to combat COVID-19, one of the most serious threats humanity has suffered in the last 100 years.
Descargas
Referencias
Cao B, Wang Y, D, Liu W, Wang J, Fan G, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382:1787-99. doi:10.1056/NEJMoa2001282
Wu CY, Jan JT, Ma SH, Kuo CJ, Juan HF, Cheng YSE, et al. Small molecules targeting severe acute respiratory syndrome human coronavirus. PNAS. 2004;101(27):10012-7. doi:10.1073/pnas.0403596101
Chan JF, Yao Y, Yeung ML, Deng W, Bao L, Jia L, et al. Treatment with lopinavir/ritonavir or interferon-b1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis. 2015;212(12):1904-13. doi:10.1093/infdis/jiv392
Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mahile M. Hydroxychloroquine and azithromycin as a treatment of COVID-19:results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi:10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
Gao J, Tian Z, Yang X. Breakthrough:chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. BioScience Trends. 2020;14(1):72-3. doi:10.5582/bst.2020.01047
Boulware D. Post-exposure prophylaxis/preemptive therapy for SARS-coronavirus-2 (COVID-19 PEP). Minneapolis, MN:University of Minnesota;2020. Disponible en:https://clinicaltrials.gov/ct2/show/NCT04308668?cond=Coronavirus&cntry=US&state=US%3AMN&draw=2&rank=1
Dalgard O. Norwegian Coronavirus Disease 2019 Study (NO COVID-19). Akhershus, Norway:Akerhus University Hospital;2019. Disponible en:https://clinicaltrials.gov/ct2/show/NCT04316377?term=chloroquine+and+covid-19&draw=2&rank=3.
Schilling W. Chloroquine/hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting (COPCOV). Oxford, UK:University of Oxford;2020. Disponible en:https://clinicaltrials.gov/ct2/show/NCT04303507?term=chloroquine+and+covid-19&draw=2&rank=1
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269-71.
Retallack H, Di Lullo E, Arias C, Knopp KA, Laurie MT, Sandoval-Espinosa C, et al. Zika virus cell tropism in the developing human brain and inhibition by azithromycin. Proc Natl Acad Sci U S A. 2016;113(50):14408-13.
Madrid PB, Panchal RG, Warren TK, Shurtleft AC, Endsley AN, Green CE, et al. Evaluation of Ebola virus inhibitors for drug repurposing. ACS Infect Dis. 2015;1(7):317-26. doi:10.1021/acsinfecdis.5b00030
Publicado
Número
Sección
Licencia
Los autores conservan sus derechos de autor y otorgan a la Revista Médica del IMSS el derecho de primera publicación. Los artículos se distribuyen bajo una Licencia Creative Commons Atribución-NoComercial-SinDerivar 4.0 Internacional, que permite su difusión siempre que se reconozca al autor y la fuente original.
